桑黃 (Phellinus linteus)（PL）一般認為具有抗發炎、保肝及免疫調節及其
他療效。然而，有關固態桑黃之體內及體外免疫特性及其分子作用機制仍
不清楚。本研究的目的是(1)檢測探討固態培養桑黃(水及95%酒精)萃取物
及多醣(SCPLP)對細胞存活率；(2)證實桑黃多醣(SCPLP)在細胞經由脂多醣
(LPS) 誘導人類單核球細胞（THP-1）之MAPK 訊息路徑、COX-2 的系統
（COX-1 及COX-2）及iNOS，Catalase 及GPX。(3) 研究桑黃多醣(SCPLP)
對非特異性，如脂多醣 (LPS) 誘導之細胞激素(IL-6、MIP-2 及TNF-α)形
成，腹腔巨噬細之胞吞噬作用及一氧化氮(NO)之形成；以及特異性，如OVA
誘導免疫球蛋白IgE 及IgG 之形成及遲發性過敏反應-掌蹼試驗之影響。XTT
試驗結果顯示，固態培養桑黃所分離之多醣（SCPLP）比其他萃取物(水及
95%乙醇)對LPS-誘導之THP-1 細胞具有更好的細胞存活率。在5.0 μg/ml
SCPLP 明顯抑制LPS 誘導所引起的iNOS 和COX-2 和Catalase 之表現，並
能抑制了磷酸化JNK 和磷酸化p38 的活化。但COX-1，ERK 及p-ERK 則
沒有顯著的表現。另一方面在動物實驗結果顯示，非特異性免疫反應實驗
中100 mg/kg/day SCPLP 可有效降低一氧化氮(NO)之形成，及具有劑量效應
的調節TNF-α，IL-6 及MIP-2 的表現，對LPS 誘導之血清或腹腔巨噬細胞。
當BALB/c 小鼠經口管餵50 mg/kg/day SCPLP 14 天後，可明顯降低左、右
掌蹼之腫脹，尤其在48 及72 小時。經口管餵SCPLP 可顯著降低由OVA
誘導之IgG 及IgE 之表現量。這些結果顯示桑黃多醣(SCPLP)，未來可發展
為具有潛力的一種免疫調節物質。 Phellinus inteus (PL) is generally believed to possess anti-inflammatory,
hepatoprotective, immunomodulatory and other therapeutic properties. However,
in vitro and in vivo immunomodulatory properties of solid cultured P. linteus
and its molecular mechanism(s) of action remain unknown. The aims of this
study were (1) to examine the effects of solid cultured P. linteus extracts
(water and 95%ethanol) and polysaccharide on cell viability；(2) to confirm of
SCPLP on the MAPK signaling pathway and COX-2 system(COX-1 and
COX-2)，iNOS，Catalase and GPX in LPS-induced human monocytic cells
(THP-1) ； and (3) to study the effects of SCPLP in non-specific (i.e.
lipopolysaccharide (LPS)-induced cytokines formation，phagocytosis and ntric
oxide (NO) generation and specific (i.e. OVA-induced specific antibodies such
as IgG and IgE generation and footpad swelling effects.) The MTT assay
showed that SCPLP possessed a better cell viability than other extracts in
LPS-induced THP-1 cells. At 5.0 μg/ml，SCPLP significantly blocked the LPS
induction of iNOS，COX-2 and GPX expression，suppressed the actiyation and
phosphorylation of JNK and p38，but not COX-1，Catalase，ERK and p-ERK.
Animal result showed that SCPLP 100mg/kg/day effectively decreased the
generation of NO，and dose-dependently down-regulated the TNF-α，IL-6 and
MIP-2 expreaaion in the LPS-induced serum or peritoneal macrophages. Mice
fed 50mg/kg/day of SCPLP for 14 days displayed a significantly (P<0.05) lesser
left or right footpad swelling at 48 and 72 h. Oral administration of SCPLP
significantly decreased the expression of anti-OVA IgG and anti-OVA IgE
levels OVA-immunization. These results that SCPLP could be developed as a
potential immunomodulator.
